PMID-34798268 – MOTS-c Relieves Hyperglycemia in Gestational Diabetes
Yin Y et al. "The mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus," Pharmacological Research, 2022;175:105987. doi:10.1016/j.phrs.2021.105987
Quick Reference
| Property | Value |
|---|---|
| PMID | 34798268 |
| DOI | 10.1016/j.phrs.2021.105987 |
| Year | 2022 |
| Journal | Pharmacological Research |
| Study Type | Animal in vivo |
| Evidence Level | V |
| Sample | Gestational diabetes mellitus (GDM) mouse model |
| Peptide(s) Studied | MOTS-C |
Key Findings
- MOTS-c significantly alleviated hyperglycemia in GDM mice
- Improved insulin sensitivity and glucose tolerance
- Protected pancreatic beta cells from GDM-induced injury
- Demonstrates metabolic benefits beyond standard T2DM models
Study Design
GDM mouse model with MOTS-c treatment. Outcomes: blood glucose levels, insulin sensitivity (OGTT, ITT), pancreatic beta-cell histology and function markers.
Limitations
- Mouse GDM model; human gestational diabetes has different pathophysiology
- Single-model validation
- No dose-response characterization
Clinical Relevance
Extends MOTS-c's metabolic evidence into gestational diabetes — a condition affecting 2-10% of pregnancies. Published in Pharmacological Research (IF ~10). While preclinical, the insulin-sensitizing mechanism is relevant to the broader metabolic application of MOTS-c.
Related
#research #animal-in-vivo #evidence-level-V